EOLS

Evolus, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001570562 Biotech & Drug Discovery

$7.11 +0.10 (+1.50%)

Oct 26 4:00 PM ET · prev $7.01

Market cap

$489.4M

Small cap

Consensus

Buy

83% Buy or better · 12 analysts

Median target

$13.00

+83% · range $12.00–20.00

Next earnings

Nov 4

in 9 days · EPS est. −$0.07

1 year

−1.5%

from $7.22 · Oct 27

30 days

−10.6%

from $7.96

52-week range

$3.94–9.30

−23% from high · low Mar 30

Avg volume 20D

762.4K

Oct 2 spike 2.07M

Short interest

5.63M

≈8.5% of shares · +1.8%

Days to cover

9.3

at average volume

Insider net

−$1.7M

0 buyers · 2 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

SecBot read BULLISH 2 reports · 90 days

Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 4, 2026

Strongest BULLISH Five institutional investors accumulated $11.6M in net new EOLS positions during Q2 2026, led by State…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Mar 17 to Mar 20 2 days of insider sells: $796.9K by 2 insiders, avg $4.87
R Mar 17 Two Evolus insiders, David Moatazedi and Rui Avelar, conducted a ser…
R Mar 17 Two Evolus insiders, including CEO David Moatazedi and executive Rui…
R Jul 8 Evolus entered into an exclusive license and distribution agreement…
S Sep 2 1 insider sell $950.0K at $9.04

Signal stack

Where each data set points today.

InsidersBEARISH

2 insiders sold $1.7M.
InstitutionsBULLISH

Q2 2026: 15 added (1 new), 10 trimmed or exited. Largest new: Point72 Asset Management, $10.5M.
AnalystsBULLISH

10 of 12 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.070 → −$0.068 over 90 days. 2 up, 1 down in 30 days.
Short sellersSTEADY

Short interest +1.8% to 5.63M shares. 9.3 days to cover, ≈8.5% of shares.
TrendDOWNTREND

11% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

$10.5M

in new stakes

Fund	Move	Shares	Value
STATE STREET CORP	ADD	1,697,294	$11.8M
Point72 Asset Management, L.P.	NEW	1,508,518	$10.5M
Assenagon Asset Management S.A.	ADD	908,180	$6.3M
CITADEL ADVISORS LLC	TRIM	506,354	$3.5M
D. E. Shaw & Co., Inc.	TRIM	336,901	$2.3M
Nuveen, LLC	DOUBLED	233,614	$1.6M
Trexquant Investment LP	TRIM	146,325	$1.0M
PRICE T ROWE ASSOCIATES INC /MD/	ADD	137,761	$957.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts

Buy 83% rate it Buy or better

Strong Buy5Buy5Hold2Sell0Strong Sell0

12-month targets · 5 analysts

$7.11 $12.00 $13.00 $20.00

Price is below the lowest target. Median implies +83%.Targets as of Oct 26, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 25, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Jun 17, 2026	BTIG REITERATE	REITERATE	Buy

Insider ledger

Form 4

bought · 0 insiders

$1.7M

sold · 2 insiders

Date	Insider	Type	Value
Sep 2, 2026	MOATAZEDI DAVID See Remarks	SELL	$950.0K
Mar 20, 2026	Avelar Rui See Remarks	SELL	$14.8K
Mar 20, 2026	MOATAZEDI DAVID See Remarks	SELL	$64.9K
Mar 17, 2026	Avelar Rui See Remarks	SELL	$146.6K
Mar 17, 2026	MOATAZEDI DAVID See Remarks	SELL	$570.6K
Mar 16, 2026	Avelar Rui See Remarks	EXERCISE	8,804 sh
Mar 16, 2026	MOATAZEDI DAVID See Remarks	EXERCISE	67,489 sh

Earnings setup

Estimates

Nov 4

reports in 9 days

−$0.07

EPS estimate, this quarter

+4%

estimate change, 90 days

2↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.070

90d

−$0.060

60d

−$0.060

30d

−$0.060

−$0.068

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.07	-$0.08–-$0.06	-12.5%	$77.6M
Next Q	$0.05	$0.02–$0.07	+15.4%	$99.4M
Current FY	-$0.05	-$0.10–-$0.03	-13.1%	$334.2M
Next FY	$0.29	$0.21–$0.38	+6.0%	$392.2M